Development of GSNO Therapeutic’s GSNOR Inhibitors

As demonstrated in the Science section, GSNORi regulates at least 56 pathophysiological drivers of many of the most important diseases of today with the most unmet medical needs. These diseases often have a complex set of drivers that makes single target/single effect drugs of limited efficacy against them. The unique advantage of GSNO Therapeutics’s GSNOR target is the multitude and directionality of responses with a single small molecule. Such positive, multi-mechanism, therapeutic effects due to inhibiting one enzyme with small molecules are rare in pharmacology. Many important diseases are based on inappropriate inflammation, oxidant/nitrosative damage, mitochondrial dysfunction, calcium dysregulation, endoplasmic reticulum stress, vascular dysfunction/hypoperfusion, hyperglycemia, misfolded proteins, MMP-9, BBB breakdown, and platelet aggregation. GSNORi inhibits all of those pathological conditions for potent therapeutic benefits.